Fayetteville-based Namida Lab, which according to a news release is the world leader in tear-based diagnostics, announced the launch of Auria™ – which is the first ever at-home breast health assessment powered by tears – on Wednesday, Oct. 12 from 5 p.m. – 7 p.m. at Fox Trail Distillery in Rogers.
Available for women ages 33-85 with an average risk of developing breast cancer (regardless of the density of their breast tissue), physicians have backed Auria™, which has over a decade of clinical trials and research. This test identifies protein biomarkers that are related to breast abnormalities through tears.
According to Namida Lab, in the United States, one in eight women will develop invasive breast cancer throughout their lifetime, with national mammography screening programs reducing breast-cancer related mortality. With that being said, only 50% of women who are eligible for screening comply, and Namida Lab is bringing this resource to market in order to lower screening barriers and increase education about breast health.
“With Auria™, the idea is to more broadly apply the technology so that we can screen more people. The easiest, most straightforward way of changing the course of the disease is to find it early,” Dr. Steve Harms, an internationally recognized breast imaging specialist, said.
As an at-home test, Auria™ provides a personalized score and classification to a level of urgency for scheduling a screening mammogram. Customers are able to schedule a one-on-one consultation with a breast health specialist to review their test results and better understand their breast health.
Dr. Anna Daily is the inventor of Auria™, and is an expert in protein biochemistry. She also has numerous peer-reviewed publication and patents on tear-based diagnostic development.
“This technology has taken over a decade of research, development and clinical studies made possible through collaborations with comprehensive breast health and cancer centers across the U.S. Identifying proteins related to breast abnormalities is only the beginning. information from the community of Auria™ customers will lay the groundwork for personalized breast health intelligence, leading to optimized diagnostic thresholds, as well as the potential for breast cancer diagnostic tests utilizing tears,” Daily said.
Due to COVID-19, there have been broad disruptions in breast care – which led to reduced mammography screenings and resulting in unknown impacts on long-term breast cancer mortality, according to Namida Lab. The lab is focused on increasing access to self-sampling for cancer screening, in accordance with the White House cancer panel recommendations.
“The team at Namida Lab has been working through the pandemic to bring Auria™ to market, to provide a means of assessing one’s breast health conveniently at home. successful clinical testing of Auria™ has allowed us to expand our vision to develop a widely accessible, inexpensive and accurate tests for other cancers,” Omid Moghadam, CEO and cofounder of Namida Lab, Inc., said.
Customers, along with their purchase , are invited to set up a personalized breast health dashboard. Auria™ is available for purchase online, and after collection, the included return packaging will allow for timely delivery to Namida’s CLIA lab. Customer’s results are reviewed by a physician and delivered to the online dashboard. Following this, customers are encouraged to request a consultation to review results.
According to Namida Lab, Auria™ is not a diagnostic test for breast cancer and does not replace a screening mammogram, but it is a high complexity, lab-developed test developed and validated through precision, accuracy and validity standards of the CLIA – availably by prescription only.
(Photo courtesy of Auria™).